CoChat
Sign Up
Cited by 2,737Acute Ischemic Stroke ManagementIntracerebral and Subarachnoid Hemorrhage ResearchAcute Myocardial Infarction Research

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

Open access
Emberson, Jonathan, Lees, Kennedy R, Lyden, Patrick, Blackwell, Lisa, Albers, Gregory, Bluhmki, Erich, Brott, Thomas, Cohen, Geoff, Davis, Stephen, Donnan, Geoffrey, Grotta, James, Howard, George, Kaste, Markku, Koga, Masatoshi, von Kummer, Ruediger, Lansberg, Maarten, Lindley, Richard I, Murray, Gordon, Olivot, Jean Marc, Parsons, Mark, Tilley, Barbara, Toni, Danilo, Toyoda, Kazunori, Wahlgren, Nils, Wardlaw, Joanna, Whiteley, William, del Zoppo, Gregory J, Baigent, Colin, Sandercock, Peter, Hacke, Werner·2014·The Lancet
DOI 10.1016/s0140-6736(14)60584-5PMC PMC4441266
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Alteplase is effective for treatment of acute ischaemic stroke but debate continues about its use after longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. We assessed the role of these factors in affecting good stroke outcome in patients given alteplase. METHODS: We did a pre-specified meta-analysis of individual patient data from 6756 patients in nine randomised trials comparing alteplase with placebo or open control. We included all completed randomised phase 3 trials of intravenous alteplase for treatment of acute ischaemic stroke for which data were available. Retrospective checks confirmed that no eligible trials had been omitted. We defined a good stroke outcome as no significant disability at 3-6 months, defined by a modified Rankin Score of 0 or 1. Additional outcomes included symptomatic intracranial haemorrhage (defined by type 2 parenchymal haemorrhage within 7 days and, separately, by the SITS-MOST definition of parenchymal type 2 haemorrhage within 36 h), fatal intracranial haemorrhage within 7 days, and 90-day mortality. FINDINGS: Alteplase increased the odds of a good stroke outcome, with earlier treatment associated with bigger proportional benefit. Treatment within 3·0 h resulted in a good outcome for 259 (32·9%) of 787 patients who received alteplase versus 176 (23·1%) of 762 who received control (OR 1·75, 95% CI 1·35-2·27); delay of greater than 3·0 h, up to 4·5 h, resulted in good outcome for 485 (35·3%) of 1375 versus 432 (30·1%) of 1437 (OR 1·26, 95% CI 1·05-1·51); and delay of more than 4·5 h resulted in good outcome for 401 (32·6%) of 1229 versus 357 (30·6%) of 1166 (OR 1·15, 95% CI 0·95-1·40). Proportional treatment benefits were similar irrespective of age or stroke severity. Alteplase significantly increased the odds of symptomatic intracranial haemorrhage (type 2 parenchymal haemorrhage definition 231 [6·8%] of 3391 vs 44 [1·3%] of 3365, OR 5·55, 95% CI 4·01-7·70, p<0·0001; SITS-MOST definition 124 [3·7%] vs 19 [0·6%], OR 6·67, 95% CI 4·11-10·84, p<0·0001) and of fatal intracranial haemorrhage within 7 days (91 [2·7%] vs 13 [0·4%]; OR 7·14, 95% CI 3·98-12·79, p<0·0001). The relative increase in fatal intracranial haemorrhage from alteplase was similar irrespective of treatment delay, age, or stroke severity, but the absolute excess risk attributable to alteplase was bigger among patients who had more severe strokes. There was no excess in other early causes of death and no significant effect on later causes of death. Consequently, mortality at 90 days was 608 (17·9%) in the alteplase group versus 556 (16·5%) in the control group (hazard ratio 1·11, 95% CI 0·99-1·25, p=0·07). Taken together, therefore, despite an average absolute increased risk of early death from intracranial haemorrhage of about 2%, by 3-6 months this risk was offset by an average absolute increase in disability-free survival of about 10% for patients treated within 3·0 h and about 5% for patients treated after 3·0 h, up to 4·5 h. INTERPRETATION: Irrespective of age or stroke severity, and despite an increased risk of fatal intracranial haemorrhage during the first few days after treatment, alteplase significantly improves the overall odds of a good stroke outcome when delivered within 4·5 h of stroke onset, with earlier treatment associated with bigger proportional benefits. FUNDING: UK Medical Research Council, British Heart Foundation, University of Glasgow, University of Edinburgh.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60584-5

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

Sorted by citations

Items 901–1,000 of 1,001

Related

See all

Metadata

Authors
Emberson, J., Lees, K. R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., Brott, T., Cohen, G., Davis, S., Donnan, G., Grotta, J., Howard, G., Kaste, M., Koga, M., von Kummer, R., Lansberg, M., Lindley, R. I., Murray, G., Olivot, J. M., Parsons, M., Tilley, B., Toni, D., Toyoda, K., Wahlgren, N., Wardlaw, J., Whiteley, W., del Zoppo, G. J., Baigent, C., Sandercock, P., & Hacke, W.
Affiliations
  • University of Oxford (GB)
  • University of Glasgow (GB)
  • Cedars-Sinai Medical Center (US)
  • Stanford University (US)
  • Boehringer Ingelheim (Germany) (DE)
  • Mayo Clinic in Florida (US)
  • University of Edinburgh (GB)
  • The University of Melbourne (AU)
  • Florey Institute of Neuroscience and Mental Health (AU)
  • The University of Texas Health Science Center at Houston (US)
  • University of Alabama at Birmingham (US)
  • Helsinki University Hospital (FI)
  • National Cerebral and Cardiovascular Center (JP)
  • The University of Sydney (AU)
  • University of Newcastle Australia (AU)
  • Sapienza University of Rome (IT)
  • Karolinska Institutet (SE)
  • Heidelberg University (DE)
Corresponding author
Baigent, Colin
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-11
Volume
384
Issue
9958
Pages
1929-1935
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(14)60584-5
PMC
PMC4441266
OpenAlex
W2165568749
Cited by
2,737
References
32
Citations by year
2026: 187 · 2025: 239 · 2024: 289 · 2023: 236 · 2022: 249 · 2021: 291 · 2020: 243 · 2019: 232 · 2018: 201 · 2017: 182 · 2016: 190 · 2015: 162 · 2014: 31
FWCI
25.13
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • Figshare (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • NOVA (University of Newcastle Australia) (submittedVersion)
Funders
  • Medical Research Council
  • British Heart Foundation
Topics
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
alteplase, intravenous thrombolysis, acute ischemic stroke, treatment delay, age, stroke severity, modified Rankin Scale, symptomatic intracranial hemorrhage, 90-day mortality, individual patient data, elderly patients, severe stroke, subgroup analysis, prognostic factors
MeSH terms
Acute Disease, Age Factors, Aged, Aged, 80 and over, Female, Fibrinolytic Agents, Humans, Infusions, Intravenous, Male, Middle Aged, Tissue Plasminogen Activator, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Intracranial Hemorrhages, Stroke, Time-to-Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review